Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Goodwin Biotechnology Stories

2014-03-24 16:25:08

PLANTATION, Fla., March 24, 2014 /PRNewswire/ -- Goodwin Biotechnology, Inc. announced an agreement with Aspyrian Therapeutics, Inc. for the technology transfer, process development, scale-up, and cGMP manufacturing of a novel Antibody Drug Conjugate (ADC) for use in Phase I clinical trials. Aspyrian Therapeutics has secured an exclusive license from the National Cancer Institute for a new ADC technology platform, Near-infrared Photoimmunotherapy (PIT), which permits highly efficient and...

2014-03-05 12:27:04

DUBLIN, March 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/w2749d/antibody_drug) has announced the addition of the "Antibody Drug Conjugates: Contract Manufacturing Market, 2014 - 2024" [http://www.researchandmarkets.com/research/w2749d/antibody_drug ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The concept of Antibody drug conjugates (ADCs) is simple - a cytotoxic /...

2013-10-01 16:25:41

PLANTATION, Fla. and MONTREAL, Oct. 1, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. announced that Alethia Biotherapeutics Inc., a privately held biotechnology company focusing on the development of therapeutic monoclonal antibodies, has contracted for the next phase of manufacturing activities for two of their leading drug candidates: -- AB-16B5, a monoclonal antibody which targets secreted clusterin for the inhibition of cancer-associated epithelial-to-mesenchymal...

2013-09-12 12:29:09

PLANTATION, Fla., Sept. 12, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. announced a key appointment that is designed to position the company for the future. SooYoung Lee, PhD has returned to Goodwin Biotechnology as Chief Operating Officer. He will report to newly appointed CEO, Karl Pinto, and will oversee all aspects of Goodwin's Contract Manufacturing Operations. SooYoung has had a distinguished career in the biological industry spanning several decades. After earning...

2013-06-03 08:29:10

PLANTATION, Fla., June 3, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) announced today the award of a sub-contract from Emergent BioSolutions for GBI to conduct some early stage proof-of-concept feasibility process development to investigate concentrating AVA filtrate for storage before the downstream process for BioThrax(®) (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the protection against anthrax disease. Anthrax is a...

2013-04-25 08:35:50

PLANTATION, Fla. and LEXINGTON, Ky., April 25, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and Coldstream Laboratories, Inc. have established a collaboration for developing and manufacturing high-potency, highly cytotoxic materials (e.g., small molecules, protein toxins, cytotoxic antibody drug conjugates, and other bioconjugates). "Over the last 20 years, GBI has offered cell culture and purification process development, scale-up, GLP manufacturing and cGMP manufacturing services...

2013-04-08 12:23:32

Innovator Companies Expected to Lose Significant Revenue Due to Biosimilar Erosion, According to a New Report from BioTrends Research Group EXTON, Pa., April 8, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, with sales forecasted to exceed $16.8 billion by 2021, manufacturers competing in the biosimilars market must adopt clear and effective strategies early in product...

2013-01-31 12:27:53

RESEARCH TRIANGLE PARK, North Carolina, January 31, 2013 /PRNewswire/ -- KEMWELL BIOPHARMA PVT LTD, a global pharmaceutical contract development and manufacturing company, announced today that its Oral Solids manufacturing facility located in Bangalore, India has successfully completed a U.S. Food and Drug Administration (USFDA) inspection. The cGMP Audit for a Pre-Approval Inspection (PAI) was triggered by a NDA filing by one of the top ten global pharmaceutical companies. This...

2012-10-25 11:22:54

PLANTATION, Fla., Oct. 25, 2012 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) has been named a three-category winner in the 2012 CMO Leadership Awards presented by Life Science Leader magazine. GBI was rated in the top 20% for Innovation, Productivity and Regulatory. "We at GBI are honored to be recognized in three categories of the CMO Leadership Awards, and consider it a testament to the quality of our people and their dedication to our customers," noted Bansi K. Bhan, Interim CEO at...

2012-06-04 02:26:37

PLANTATION, Fla. and HOUSTON, June 4, 2012 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and The University of Texas MD Anderson Cancer Center jointly announce a collaboration for process development and GMP manufacturing of a fusion protein composed of a vascular endothelial growth factor (VEGF) and the recombinant toxin, Gelonin (rGel), conjugated to a DOTA chelator. The fusion protein targets the tumor neovasculature, or blood supply, and inhibits tumor growth, and the...